Table 3.
The overview of analytical performance of Tg-iMRM-MS established in Taiwan
| Item | Details | Result | ||
|---|---|---|---|---|
| 1. Assay development | ||||
| Transition selection | Target and internal standard peptides | FSP2 (704.04/586.90, 704.04/687.5), FSP4 (709.04/591.89, 709/04/697.5) | ||
| Collision energy optimization | Default ± 10 | y7: 33.2; y12: 38.2 | ||
| 2. Reportable range | ||||
| Calibration curve | Standard serum or pooled clinical serum, serial dilution | 0.2 ~ 13 ng/mL | ||
| LOD | Lowest detectable concentration | 0.1 ng/mL | ||
| LOQ | Lowest quantifiable concentration, CV < 20% | 0.2 ng/mL | ||
| 3. Accuracy | Evaluated by QC samples, deviation < 20% | QC_mid: 7.8%; QC_high: 8% | ||
| 4. Precision | Evaluated by QC samples, deviation < 20% | |||
| Within-day repeatability | 2 or 3 QC samples, 4 replicates/day, 3 ~ 5 days | QC_low: 10.07%; QC_mid: 7.52%; QC_high: 5.49% | ||
| Between-day reproducibility | 2 or 3 QC samples, 1 replicate/day, 7 ~ 10 days | QC_low: 9.82%; QC_mid: 7.97%; QC_high: 9.92% | ||
| 5. Sensitivity | LOQ | 0.2 ng/mL | ||
| 6. Specificity | Signal overlay of endogenous and internal standard peptides | |||
| 7. Interference | Hemolysis, deviation < 20% | < 25% hemolysis (62.5–125 mg/dL) is tolerated | ||
| 8. Stability | Room temperature (20 °C); 4 °C; -80 °C | RT: 48 h; 4 °C: 48 h; -80 °C: > 1yr | ||
| 9. Proficiency test |
20–35 QCs and clinical samples exchanged with reference laboratory |
r2 = 0.996, slope = 0.9287 | ||